Teva In-Focus: A Webinar Series for the Investment Community Focusing on Teva’s R&D Activities

  Teva In-Focus: A Webinar Series for the Investment Community Focusing on
  Teva’s R&D Activities

           New Therapeutic Entities (NTE) - from Process to Product

          Teva unveils new pipeline assets from its 2013 NTE program

    - Embargoed: December 4^th, 8:00am Eastern Time (2nd Teva R&D In-Focus
                                  Webinar) -

Business Wire

JERUSALEM -- December 4, 2013

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced that 15 new
projects have entered its development pipeline from its New Therapeutic
Entities (NTE) program.

Launched one year ago, the NTE program has delivered new pipeline assets in
major therapeutic areas, including:

  *Innovation in the abuse deterrent delivery of opioids for pain
  *Significant development in the delivery of a key schizophrenia treatment
  *New targeted release approach to improve the safety profile of a common
    treatment for Crohn's Disease

Based on known molecules that are formulated, delivered, or used in a novel
way to address unmet patient need and improve adherence and efficacy, the NTE
program is a major element in Teva's strategy for growth. It was established
to leverage Teva's vast molecular catalogue, advanced technological
capabilities and extensive specialty drug development expertise. The program
was designed to "industrialize" the process of generating, evaluating and
rapidly and cost-effectively developing new specialty medicine concepts, which
bring distinct and definite advantages over current therapies

"Bringing 15 new development programs into the pipeline in one year is
exciting," said Dr. Michael Hayden, Teva's President of Global R&D and Chief
Scientific Officer. "Moreover, the products we will be developing represent
genuine advances on existing therapies, and will deliver real benefit to
patients. The rigorous process we have established to identify and evaluate
these projects will support successful delivery of these new treatments for
the patients that need them."

An infographic overview of the process and projects can be accessed here.
However, the full NTE story can be seen and heard during the Teva In-Focus NTE
webinar (see below for log-in details). The webinar will include an in-depth
review of certain key projects from the 2013 program, outlining the global
market and unmet needs for each one. It will highlight the approach and
technologies Teva is using to improve upon known molecules to address these
unmet needs, and provide a clear picture of the development plans and expected
therapeutic benefits.

Dr. Michael Hayden, Teva’s President of Global R&D and Chief Scientific
Officer, will lead the webinar and will be joined by key leaders from Teva’s
NTE program.

A question and answer session will follow the presentation.

Webinar access details:

Meeting Title:        Teva NTE Webinar
Meeting Date:          December  4^th, 2013
Meeting Time:          8:00 AM [Eastern Time]
Duration:              1 Hour 30 Minutes
                      
Webcast Link:          http://www.media-server.com/m/p/m753rv5e
                      
Dial-in details:       
                      
US Toll Free           1-866-318-8620
International          1-617-399-5139
Participant Passcode   92011346

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is a leading global
pharmaceutical company, committed to increasing access to high-quality
healthcare by developing, producing and marketing affordable generic drugs as
well as innovative and specialty pharmaceuticals and active pharmaceutical
ingredients. Headquartered in Israel, Teva is the world's leading generic drug
maker, with a global product portfolio of more than 1,000 molecules and a
direct presence in about 60 countries. Teva's branded businesses focus on CNS,
oncology, pain, respiratory and women's health therapeutic areas as well as
biologics. Teva currently employs approximately 46,000 people around the world
and reached $20.3 billion in net revenues in 2012.

Teva's Safe Harbor Statement under the U. S. Private Securities Litigation
Reform Act of 1995:

This release contains forward-looking statements, which express the current
beliefs and expectations of management. Such statements involve a number of
known and unknown risks and uncertainties that could cause our future results,
performance or achievements to differ significantly from the results,
performance or achievements expressed or implied by such forward-looking
statements. Important factors that could cause or contribute to such
differences include risks relating to: the ability to reduce operating
expenses to the extent and during the timeframe intended by our cost
restructuring program; our ability to develop and commercialize additional
pharmaceutical products, including our ability to develop, manufacture, market
and sell biopharmaceutical products, competition for our innovative medicines,
especially COPAXONE® (including competition from innovative
orally-administered alternatives, as well as from potential purported generic
equivalents), competition for our generic products (including from other
pharmaceutical companies and as a result of increased governmental pricing
pressures), competition for our specialty pharmaceutical businesses, our
ability to achieve expected results through our specialty, including
innovative, R&D efforts, the effectiveness of our patents and other
protections for innovative products, decreasing opportunities to obtain U.S.
market exclusivity for significant new generic products, our ability to
identify, consummate and successfully integrate acquisitions and license
products, our ability to reduce operating expenses to the extent and during
the timeframe intended by our cost restructuring program, uncertainties
relating to the replacement of and transition to a new President & Chief
Executive Officer, the effects of increased leverage as a result of recent
acquisitions, the extent to which any manufacturing or quality control
problems damage our reputation for high quality production and require costly
remediation, our potential exposure to product liability claims to the extent
not covered by insurance, increased government scrutiny in both the U.S. and
Europe of our settlement agreements with brand companies and liabilities
arising from class action litigation and other third-party claims relating to
such agreements, potential liability for sales of generic medicines prior to a
final resolution of outstanding patent litigation, our exposure to currency
fluctuations and restrictions as well as credit risks, the effects of reforms
in healthcare regulation and pharmaceutical pricing and reimbursement, any
failures to comply with complex Medicare and Medicaid reporting and payment
obligations, governmental investigations into sales and marketing practices,
particularly for our specialty medicines (and our ongoing FCPA investigations
and related matters), uncertainties surrounding the legislative and regulatory
pathways for the registration and approval of biotechnology-based medicines,
adverse effects of political or economical instability, corruption, major
hostilities or acts of terrorism on our significant worldwide operations,
interruptions in our supply chain or problems with our information technology
systems that adversely affect our complex manufacturing processes, any failure
to retain key personnel or to attract additional executive and managerial
talent, the impact of continuing consolidation of our distributors and
customers, variations in patent laws that may adversely affect our ability to
manufacture our products in the most efficient manner, potentially significant
impairments of intangible assets and goodwill, potential increases in tax
liabilities resulting from challenges to our intercompany arrangements, the
termination or expiration of governmental programs or tax benefits,
environmental risks and other factors that are discussed in our Annual Report
on Form 20-F for the year ended December 31, 2012 and in our other filings
with the U.S. Securities and Exchange Commission. Forward-looking statements
speak only as of the date on which they are made and the Company undertakes no
obligation to update or revise any forward looking statement, whether as a
result of new information, future events or otherwise.

Contact:

Teva Pharmaceutical Industries Ltd.
IR:
Kevin C. Mannix
United States
215-591-8912
or
Ran Meir
United States
215-591-3033
or
Tomer Amitai
Israel
972 (3) 926-7656
or
PR:
Iris Beck Codner
Israel
972 (3) 926-7687
or
Denise Bradley
United States
215-591-8974
 
Press spacebar to pause and continue. Press esc to stop.